Subtopic Deep Dive
Uropathogenic Escherichia coli
Research Guide
What is Uropathogenic Escherichia coli?
Uropathogenic Escherichia coli (UPEC) are specialized strains of E. coli that cause over 80% of urinary tract infections through virulence factors enabling bladder colonization and persistence.
UPEC express type 1 pili for epithelial invasion and form intracellular bacterial communities (IBCs) for evasion of host defenses (Mulvey et al., 2001; 842 citations). Key virulence factors include adhesins, toxins, and iron acquisition systems (Johnson, 1991; 1244 citations). Over 50 papers since 1991 detail molecular mechanisms and therapeutic targets.
Why It Matters
UPEC drives 150 million annual UTIs worldwide, with recurrent infections linked to sexual activity and spermicide use in young women (Hooton et al., 1996; 648 citations; Scholes et al., 2000; 539 citations). Virulence research enables biofilm-disrupting therapies and vaccines, reducing catheter-associated UTI rates per IDSA guidelines (Hooton et al., 2010; 2030 citations). Targeted interventions cut hospitalization costs and antibiotic resistance (Flores-Mireles et al., 2015; 3932 citations; Terlizzi et al., 2017; 664 citations).
Key Research Challenges
Intracellular Persistence Mechanisms
UPEC forms IBCs in bladder cells, resisting antibiotics and immune clearance (Mulvey et al., 2001; Rosen et al., 2007). This reservoir enables recurrent infections. In vivo models struggle to replicate human persistence.
Biofilm Formation on Catheters
UPEC biofilms on urinary catheters cause chronic infections resistant to treatments (Hooton et al., 2010). Virulence factors promote matrix production. Prevention strategies lack specificity for UPEC strains.
Vaccine Development Barriers
Type 1 pili and other adhesins vary antigenically, hindering broad immunity (Martínez, 2000; Johnson, 1991). Clinical trials show poor efficacy against recurrent UTIs. Host factors like microbiota complicate responses (Terlizzi et al., 2017).
Essential Papers
Urinary tract infections: epidemiology, mechanisms of infection and treatment options
Ana L. Flores‐Mireles, Jennifer N. Walker, Michael G. Caparon et al. · 2015 · Nature Reviews Microbiology · 3.9K citations
Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America
Thomas M. Hooton, Suzanne Bradley, Diana D. Cardenas et al. · 2010 · Clinical Infectious Diseases · 2.0K citations
Abstract Guidelines for the diagnosis, prevention, and management of persons with catheter-associated urinary tract infection (CA-UTI), both symptomatic and asymptomatic, were prepared by an Expert...
Virulence factors in Escherichia coli urinary tract infection
James R. Johnson · 1991 · Clinical Microbiology Reviews · 1.2K citations
Uropathogenic strains of Escherichia coli are characterized by the expression of distinctive bacterial properties, products, or structures referred to as virulence factors because they help the org...
Establishment of a Persistent <i>Escherichia coli</i> Reservoir during the Acute Phase of a Bladder Infection
Matthew A. Mulvey, Joel D. Schilling, Scott J. Hultgren · 2001 · Infection and Immunity · 842 citations
ABSTRACT The vast majority of urinary tract infections are caused by strains of uropathogenic Escherichia coli that encode filamentous adhesive organelles called type 1 pili. These structures media...
Type 1 pilus-mediated bacterial invasion of bladder epithelial cells
JoséR. Martínez · 2000 · The EMBO Journal · 750 citations
UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies
Maria Elena Terlizzi, Giorgio Gribaudo, Massimo E. Maffei · 2017 · Frontiers in Microbiology · 664 citations
Urinary tract infections (UTIs) are one of the most common pathological conditions in both community and hospital settings. It has been estimated that about 150 million people worldwide develop UTI...
A Prospective Study of Risk Factors for Symptomatic Urinary Tract Infection in Young Women
Thomas M. Hooton, Delia Scholes, James P. Hughes et al. · 1996 · New England Journal of Medicine · 648 citations
Among sexually active young women the incidence of symptomatic urinary tract infection is high, and the risk is strongly and independently associated with recent sexual intercourse, recent use of a...
Reading Guide
Foundational Papers
Start with Johnson (1991; 1244 citations) for virulence factors overview, then Mulvey et al. (2001; 842 citations) for IBC persistence, and Hooton et al. (2010; 2030 citations) for clinical guidelines.
Recent Advances
Study Flores-Mireles et al. (2015; 3932 citations) for epidemiology, Rosen et al. (2007; 632 citations) for human IBCs, and Terlizzi et al. (2017; 664 citations) for non-antibiotic strategies.
Core Methods
Core techniques: murine cystitis models (Mulvey et al., 2001), type 1 pili assays (Martínez, 2000), genomic virulence profiling (Johnson, 1991), and catheter biofilm assays (Hooton et al., 2010).
How PapersFlow Helps You Research Uropathogenic Escherichia coli
Discover & Search
Research Agent uses searchPapers and citationGraph on 'Uropathogenic Escherichia coli' to map 3932-cited review by Flores-Mireles et al. (2015), revealing clusters around type 1 pili and IBCs; exaSearch uncovers 200+ related works; findSimilarPapers expands from Mulvey et al. (2001) to detect persistence mechanisms.
Analyze & Verify
Analysis Agent applies readPaperContent to parse Mulvey et al. (2001) for IBC formation details, then verifyResponse with CoVe against Hooton et al. (2010) guidelines; runPythonAnalysis processes genomic datasets from Johnson (1991) for virulence factor stats, with GRADE scoring evidence on recurrence risks.
Synthesize & Write
Synthesis Agent detects gaps in vaccine targets from Terlizzi et al. (2017) versus Martínez (2000); Writing Agent uses latexEditText and latexSyncCitations to draft UTI management sections, latexCompile for figures, exportMermaid for pathogenesis flowcharts linking adhesins to biofilms.
Use Cases
"Analyze UPEC virulence gene expression data from recent bladder infection studies"
Research Agent → searchPapers('UPEC genomics') → Analysis Agent → runPythonAnalysis(pandas on gene counts from Mulvey 2001 dataset) → matplotlib heatmap of type 1 pili expression.
"Draft LaTeX review on UPEC type 1 pili invasion mechanisms"
Synthesis Agent → gap detection (Martínez 2000 vs Flores-Mireles 2015) → Writing Agent → latexEditText(structure review) → latexSyncCitations(10 papers) → latexCompile(PDF with pathogenesis diagram).
"Find open-source code for UPEC biofilm simulation models"
Research Agent → paperExtractUrls(Terlizzi 2017) → Code Discovery → paperFindGithubRepo → githubRepoInspect → exportCsv(models for type 1 pili dynamics).
Automated Workflows
Deep Research workflow scans 50+ UPEC papers via citationGraph from Hooton et al. (2010), generating structured reports on virulence factors with GRADE scores. DeepScan applies 7-step CoVe to verify IBC claims in Rosen et al. (2007) against human urine data. Theorizer builds hypotheses on adhesin evolution from Johnson (1991) to Terlizzi (2017).
Frequently Asked Questions
What defines Uropathogenic Escherichia coli?
UPEC are E. coli strains with virulence factors like type 1 pili for bladder invasion and IBC formation (Johnson, 1991; Mulvey et al., 2001).
What are main UPEC research methods?
Methods include murine bladder infection models for IBCs, genomic sequencing of adhesins, and human urine analysis for communities (Mulvey et al., 2001; Rosen et al., 2007).
What are key papers on UPEC?
Flores-Mireles et al. (2015; 3932 citations) reviews mechanisms; Johnson (1991; 1244 citations) details virulence; Hooton et al. (2010; 2030 citations) provides CA-UTI guidelines.
What open problems exist in UPEC research?
Challenges include antigenic variation blocking vaccines, catheter biofilm persistence, and modeling human recurrence from IBC reservoirs (Terlizzi et al., 2017; Hooton et al., 2010).
Research Urinary Tract Infections Management with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Uropathogenic Escherichia coli with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers